Allogeneic Bone Marrow Transplantation (BMT) and Peripheral Blood Stem Cell Transplantation (PBSCT) for Patients with Hematological Malignancies.

Allogeneic bone marrow transplantation (BMT) from HLA-identical sibling donors has been accepted as a cure-oriented treatment for patients with hematological malignancies. BMT has been, however, a possible modality of treatment only for one-third of the patients because of the lack of HLA-matched related donors. In December 1991, the Japanese Marrow Donor Program (JMD) was organized and we could identify unrelated donors through JMDP, Recently, allogeneic peripheral blood stem cell transplantation (PBSCT) has been developed using granulocyte-colony stimulating factor (G-CSF) mobilized peripheral blood stem cells. Allo-PBSCT results in rapid hematological recovery without excessive acute graft-versus-host disease compared with BMT patients and longer follow-up period will be required to assess the real efficacy of allo-PBSCT